{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:12:22Z","timestamp":1718903542812},"reference-count":262,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.blre.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T13:12:54Z","timestamp":1479301974000},"page":"101-118","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["After 10 years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera"],"prefix":"10.1016","volume":"31","author":[{"given":"Jacob","family":"Grinfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna L","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2016.11.001_bb0005","series-title":"WHO classification of Tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"7037","key":"10.1016\/j.blre.2016.11.001_bb0010","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"9464","key":"10.1016\/j.blre.2016.11.001_bb0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.blre.2016.11.001_bb0020","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera","volume":"139","author":"Scott","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2141.2008.07526.x","article-title":"Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?","volume":"144","author":"Wardrop","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0045","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0050","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0065","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2141.2007.06741.x","article-title":"Amendment to the guideline for diagnosis and investigation of polycythaemia\/erythrocytosis","volume":"138","author":"McMullin","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0080","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","article-title":"Guideline for the diagnosis and management of myelofibrosis","volume":"158","author":"Reilly","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V95.1.19","article-title":"The Jak-Stat pathway in normal and perturbed hematopoiesis","volume":"95","author":"Ward","year":"2000","journal-title":"Blood"},{"issue":"52","key":"10.1016\/j.blre.2016.11.001_bb0110","doi-asserted-by":"crossref","first-page":"31282","DOI":"10.1074\/jbc.270.52.31282","article-title":"Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells","volume":"270","author":"Penta","year":"1995","journal-title":"J Biol Chem"},{"issue":"49","key":"10.1016\/j.blre.2016.11.001_bb0115","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"issue":"49","key":"10.1016\/j.blre.2016.11.001_bb0120","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0125","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1091\/mbc.E02-06-0342","article-title":"Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain","volume":"14","author":"Saharinen","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018522","article-title":"Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation","volume":"6","author":"Sanz","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0140","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011157","article-title":"JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors","volume":"5","author":"Dusa","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0155","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases","volume":"20","author":"Toms","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0160","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.11.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.blre.2016.11.001_bb0170","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.exphem.2009.09.009","article-title":"Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation","volume":"37","author":"Laubach","year":"2009","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.pas.0000213338.25111.d3","article-title":"Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation","volume":"31","author":"Aboudola","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"10.1016\/j.blre.2016.11.001_bb0190","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0195","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0200","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0210","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells","volume":"108","author":"Garcon","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2016.11.001_bb0215","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2016.11.001_bb0220","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2016.11.001_bb0225","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0230","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2005-07-3037","article-title":"Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells","volume":"107","author":"Zeuner","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0235","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera","volume":"338","author":"Silva","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0240","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2016.11.001_bb0245","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders","volume":"359","author":"Zhao","year":"2008","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.blre.2016.11.001_bb0250","doi-asserted-by":"crossref","first-page":"32334","DOI":"10.1074\/jbc.M803813200","article-title":"Effects of the JAK2 inhibitor, AZ960, on Pim\/BAD\/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2","volume":"283","author":"Gozgit","year":"2008","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.blre.2016.11.001_bb0255","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/blood-2009-03-209544","article-title":"Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells","volume":"115","author":"Will","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.11.001_bb0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2407-11-24","article-title":"Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival","volume":"11","author":"Rubert","year":"2011","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0265","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2009-02-206573","article-title":"ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling","volume":"114","author":"Wood","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0270","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0275","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"issue":"42","key":"10.1016\/j.blre.2016.11.001_bb0280","doi-asserted-by":"crossref","first-page":"15190","DOI":"10.1073\/pnas.1401873111","article-title":"JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response","volume":"111","author":"Chen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7265","key":"10.1016\/j.blre.2016.11.001_bb0285","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0290","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.celrep.2012.08.016","article-title":"Three distinct patterns of histone H3Y41 phosphorylation mark active genes","volume":"2","author":"Dawson","year":"2012","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0295","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.blre.2016.11.001_bb0300","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0305","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm.3057","article-title":"CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress","volume":"19","author":"Chow","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0310","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nm.3126","article-title":"Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia","volume":"19","author":"Ramos","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0315","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0320","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0325","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2010-12-327593","article-title":"Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0330","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0335","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.exphem.2006.12.007","article-title":"In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele","volume":"35","author":"Gaikwad","year":"2007","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0340","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0345","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.exphem.2007.07.005","article-title":"Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD\/SCID mice","volume":"35","author":"Ishii","year":"2007","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0350","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2008-02-137877","article-title":"The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity","volume":"112","author":"James","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0355","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2016.11.001_bb0360","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.11.001_bb0365","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain clonal expansion","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001576","article-title":"Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion","volume":"11","author":"Kent","year":"2013","journal-title":"PLoS Biol"},{"issue":"12","key":"10.1016\/j.blre.2016.11.001_bb0375","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.13074","article-title":"The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders","volume":"93","author":"Theocharides","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0380","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2008-04-154708","article-title":"The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation","volume":"112","author":"Van Pelt","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2016.11.001_bb0385","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2012-05-430926","article-title":"Impact of isolated germline JAK2V617I mutation on human hematopoiesis","volume":"121","author":"Mead","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0390","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.V90.1.64","article-title":"Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia","volume":"90","author":"Petzer","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0395","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.thj.6200051","article-title":"Normal and chronic phase CML hematopoietic cells repopulate NOD\/SCID bone marrow with different kinetics and cell lineage representation","volume":"1","author":"Dazzi","year":"2000","journal-title":"Hematol J"},{"issue":"16","key":"10.1016\/j.blre.2016.11.001_bb0400","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"issue":"7051","key":"10.1016\/j.blre.2016.11.001_bb0405","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.blre.2016.11.001_bb0410","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1182\/blood-2009-09-245928","article-title":"Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins","volume":"115","author":"Wajapeyee","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0415","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2011-02-335042","article-title":"Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"issue":"9501","key":"10.1016\/j.blre.2016.11.001_bb0420","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0425","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0430","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0435","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0440","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0445","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2016.11.001_bb0450","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0455","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0460","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0465","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0470","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0475","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0480","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0485","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0490","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0495","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2014.52","article-title":"Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice","volume":"28","author":"Akada","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0500","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0505","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"issue":"13","key":"10.1016\/j.blre.2016.11.001_bb0510","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0515","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2012.079129","article-title":"Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia","volume":"98","author":"Godfrey","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0520","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2016.11.001_bb0525","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0530","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0535","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients","volume":"39","author":"Stein","year":"2011","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0540","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0545","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2","volume":"210","author":"Jutzi","year":"2013","journal-title":"J Exp Med"},{"issue":"22","key":"10.1016\/j.blre.2016.11.001_bb0550","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1182\/blood-2014-09-603043","article-title":"Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?","volume":"124","author":"Godfrey","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0555","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0560","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germline JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0565","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0570","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0575","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2009.110","article-title":"The \u2018GGCC\u2019 haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera","volume":"23","author":"Olcaydu","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.blre.2016.11.001_bb0580","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0585","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0590","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620713489144","article-title":"Inherited predisposition to myeloproliferative neoplasms","volume":"4","author":"Jones","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0595","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.leukres.2011.09.029","article-title":"Influence of JAK2 46\/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms","volume":"36","author":"Alvarez-Larran","year":"2012","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0600","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2013.21","article-title":"JAK2V617F allele burden, JAK2 46\/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0605","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/leu.2014.48","article-title":"The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms","volume":"28","author":"Oddsson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.11.001_bb0610","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0615","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germline variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0620","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/emboj.2009.97","article-title":"Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis","volume":"28","author":"Garcia","year":"2009","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0625","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2010-07-296921","article-title":"The dominant negative beta isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients","volume":"118","author":"Varricchio","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2016.11.001_bb0630","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2012-05-433466","article-title":"A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation","volume":"120","author":"Poletto","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2016.11.001_bb0635","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1182\/blood-2012-02-411215","article-title":"A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera","volume":"119","author":"Hernandez-Boluda","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0640","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.blre.2016.11.001_bb0645","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0650","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2016.11.001_bb0655","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1182\/blood-2010-09-306506","article-title":"Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera","volume":"117","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0660","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bcmd.2012.11.009","article-title":"MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients","volume":"50","author":"Zhan","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0665","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2016.11.001_bb0670","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/leusup.2014.13","article-title":"The polycythemia vera stem cell","volume":"3","author":"Spivak","year":"2014","journal-title":"Leuk Suppl"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0675","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ng.467","article-title":"A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium","volume":"41","author":"Soranzo","year":"2009","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0680","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ng.466","article-title":"Multiple loci influence erythrocyte phenotypes in the CHARGE consortium","volume":"41","author":"Ganesh","year":"2009","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002113","article-title":"Multiple loci are associated with white blood cell phenotypes","volume":"7","author":"Nalls","year":"2011","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0690","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/hmg\/dds534","article-title":"GWAS of blood cell traits identifies novel associated loci and epistatic interactions in Caucasian and African-American children","volume":"22","author":"Li","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0695","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.462","article-title":"Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels","volume":"41","author":"Chambers","year":"2009","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb0700","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ng.456","article-title":"Common variants in TMPRSS6 are associated with iron status and erythrocyte volume","volume":"41","author":"Benyamin","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0705","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000084673","article-title":"Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia","volume":"113","author":"Thiele","year":"2005","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0710","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.blre.2016.11.001_bb0715","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11010-012-1326-7","article-title":"A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q\/K539L","volume":"367","author":"Gnanasambandan","year":"2012","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0720","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2015.128546","article-title":"STAT1 activation in association with JAK2 exon 12 mutations","volume":"101","author":"Godfrey","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0725","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","article-title":"How I treat essential thrombocythemia","volume":"117","author":"Beer","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0730","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2016.11.001_bb0735","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2016.11.001_bb0740","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3324\/haematol.2010.029306","article-title":"Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0745","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","article-title":"Guidelines for the diagnosis, investigation and management of polycythaemia\/erythrocytosis","volume":"130","author":"McMullin","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0750","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"Bench","year":"2013","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.blre.2016.11.001_bb0755","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0760","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.13812","article-title":"Management of polycythaemia vera: a critical review of current data","volume":"172","author":"McMullin","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0765","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2141.2005.05517.x","article-title":"An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia","volume":"129","author":"Johansson","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0770","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/sj.leu.2404908","article-title":"Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?","volume":"22","author":"Cassinat","year":"2008","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.blre.2016.11.001_bb0775","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0780","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0785","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9343(96)00351-8","article-title":"Inapparent polycythemia vera: an unrecognized diagnosis","volume":"102","author":"Lamy","year":"1997","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0790","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJMe1213283","article-title":"Polycythemia vera, the hematocrit, and blood-volume physiology","volume":"368","author":"Spivak","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0795","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0800","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.23617","article-title":"Masked polycythemia vera diagnosed according to WHO and BCSH classification","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb0805","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.13080","article-title":"A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera","volume":"167","author":"Lussana","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0810","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12552","article-title":"Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes","volume":"96","author":"Alvarez-Larran","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0815","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol."},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0820","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2016.11.001_bb0825","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ajh.23554","article-title":"World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations\u2013the Danish experience","volume":"88","author":"Madelung","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0830","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.13047","article-title":"The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera","volume":"167","author":"Ancochea","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0835","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0840","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0845","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb0850","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0855","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"issue":"8102","key":"10.1016\/j.blre.2016.11.001_bb0860","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.blre.2016.11.001_bb0865","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0870","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0875","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0880","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0885","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4065\/78.2.174","article-title":"Polycythemia vera: a comprehensive review and clinical recommendations","volume":"78","author":"Tefferi","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0890","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0895","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb0900","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"issue":"24","key":"10.1016\/j.blre.2016.11.001_bb0905","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1002\/cncr.24664","article-title":"Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera","volume":"115","author":"Gangat","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0910","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/107602969900500301","article-title":"Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia","volume":"5","author":"Michiels","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0915","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0920","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb0925","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.blre.2016.11.001_bb0930","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb0935","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.thj.6200250","article-title":"Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy","volume":"4","author":"Kiladjian","year":"2003","journal-title":"Hematol J"},{"issue":"14","key":"10.1016\/j.blre.2016.11.001_bb0940","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.11.001_bb0945","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0950","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0955","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0960","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","article-title":"Platelet activation and inhibition in polycythemia vera and essential thrombocythemia","volume":"121","author":"Patrono","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0965","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.11.001_bb0970","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006503.pub3","article-title":"Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia","volume":"4","author":"Squizzato","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb0975","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2141.1997.362682.x","volume":"97","year":"1997","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb0980","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb0985","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","volume":"44","year":"1981","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb0990","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.1984.2.6.558","article-title":"Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia","volume":"2","author":"Brusamolino","year":"1984","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb0995","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients","volume":"85","author":"Passamonti","year":"2000","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb1000","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb1005","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.2830170402","article-title":"Treatment of polycythemia vera with hydroxyurea","volume":"17","author":"Donovan","year":"1984","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.blre.2016.11.001_bb1015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2016.11.001_bb1020","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb1025","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","article-title":"Acquired DNA mutations associated with in vivo hydroxyurea exposure","volume":"95","author":"Hanft","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb1030","first-page":"2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients >65years of age. The French Polycythemia Study Group Blood","volume":"89","author":"Najean","year":"1997"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb1035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.blre.2016.11.001_bb1040","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1045","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1050","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb1055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone","volume":"56","author":"Massaro","year":"1997","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb1060","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2016.11.001_bb1065","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb1070","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1075","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3324\/haematol.2011.053348","article-title":"Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera","volume":"97","author":"Kuriakose","year":"2012","journal-title":"Haematologica"},{"issue":"32","key":"10.1016\/j.blre.2016.11.001_bb1080","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb1085","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/leu.2013.303","article-title":"Use of the 46\/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNalpha treatment","volume":"28","author":"Hasan","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb1090","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Quintas-Cardama","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2016.11.001_bb1100","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/j.clml.2013.05.015","article-title":"Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide","volume":"13","author":"Ahn","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1110","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1115","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb1125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb1130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor Imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb1135","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb1140","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"33","key":"10.1016\/j.blre.2016.11.001_bb1145","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2016.11.001_bb1150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2016.11.001_bb1155","doi-asserted-by":"crossref","unstructured":"Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, et al. The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Blood. 124(21):3168\u20138.","DOI":"10.1182\/blood.V124.21.3168.3168"},{"issue":"9","key":"10.1016\/j.blre.2016.11.001_bb1160","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2362.2010.02334.x","article-title":"Polycythemia vera-associated pruritus and its management","volume":"40","author":"Saini","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.blre.2016.11.001_bb1165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon alpha in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb1170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","article-title":"Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy","volume":"22","author":"Griesshammer","year":"2008","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb1175","first-page":"1477","article-title":"The management and outcome of 18 pregnancies in women with polycythemia vera","volume":"90","author":"Robinson","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.11.001_bb1180","series-title":"Royal college of obstetricians and gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium","year":"2015"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1185","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms","volume":"162","author":"Sekhar","year":"2013","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.blre.2016.11.001_bb1190","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1200","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2016.11.001_bb1205","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb1210","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2016.11.001_bb1215","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb1220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb1225","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb1230","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb1235","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb1240","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb1245","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2016.11.001_bb1250","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.blre.2016.11.001_bb1255","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2016.11.001_bb1260","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.11.001_bb1265","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/leu.2012.267","article-title":"Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases","volume":"27","author":"Voso","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2016.11.001_bb1270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3324\/haematol.2013.091454","article-title":"Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase","volume":"99","author":"Brecqueville","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2016.11.001_bb1275","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.blre.2016.11.001_bb1280","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2016.11.001_bb1285","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2012.064683","article-title":"Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2016.11.001_bb1290","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2012.065375","article-title":"Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative disorders: an analysis of 636 cases","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"issue":"36","key":"10.1016\/j.blre.2016.11.001_bb1295","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"Makishima","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2016.11.001_bb1300","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2016.11.001_bb1305","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.blre.2016.11.001_bb1310","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16301072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16301072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T16:31:47Z","timestamp":1718901107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16301072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":262,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0268960X16301072"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2016.11.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}